Amiodarone Hydrochloride
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Amiodarone Hydrochloride
- Amiodarone Hydrochloride: Repurposing Evaluation — Prediction Data Unavailable
Amiodarone Hydrochloride: Repurposing Evaluation — Prediction Data Unavailable
One-Sentence Summary
Amiodarone hydrochloride is a well-established Class III antiarrhythmic agent used globally for the management of life-threatening ventricular arrhythmias and atrial fibrillation. The current Evidence Pack contains no TxGNN repurposing predictions for this drug — the prediction pipeline could not be completed due to a missing DrugBank identifier and unresolved regulatory data, representing a blocking data gap. A complete repurposing evaluation cannot be produced at this time; the recommended action is to resolve upstream data issues and re-run the pipeline.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in Evidence Pack (see Drug Background below) |
| Predicted New Indication | Not available — TxGNN prediction not completed |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A |
| South Africa Market Status | Not marketed (0 SAHPRA registrations on file) |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Drug Background
Although the automated pipeline did not retrieve mechanism of action or original indication data, amiodarone hydrochloride is a well-characterised agent in clinical pharmacology. This context is provided to support remediation planning.
Established clinical indications:
- Haemodynamically unstable ventricular tachycardia and ventricular fibrillation (acute management)
- Atrial fibrillation and flutter (rate and rhythm control)
- Paroxysmal supraventricular tachycardias (second-line)
Mechanism of action (from clinical literature): Amiodarone is a Vaughan Williams Class III antiarrhythmic. Its primary action is blockade of cardiac potassium channels (I_Kr, I_Ks), prolonging the action potential duration and effective refractory period across atrial and ventricular tissue. It also exhibits Class I (sodium channel), Class II (non-competitive beta-adrenergic), and Class IV (calcium channel) properties, which accounts for both its broad antiarrhythmic efficacy and its extensive adverse-effect profile.
Important note on market status: Amiodarone is included on the WHO Model List of Essential Medicines and is marketed as a generic product in the vast majority of countries worldwide, including many African markets. The “Not marketed / 0 SAHPRA registrations” result returned by the pipeline is almost certainly a data retrieval failure rather than a true reflection of market availability. Manual verification against the SAHPRA online medicines register is essential before drawing any regulatory conclusions.
Safety Considerations
No drug-specific safety data was retrievable via the automated pipeline for this submission.
Please refer to the SAHPRA-approved Professional Information (PI) for complete safety information. Report adverse drug reactions to SAHPRA via the MedSafety online ADR reporting portal.
As a clinical reminder for evaluation teams, amiodarone carries several black-box–level risks well documented in the literature. Any future repurposing study protocol must address:
- Thyroid toxicity — Both hypothyroidism and hyperthyroidism (amiodarone contains ~37% iodine by weight); thyroid function must be monitored before and during treatment
- Pulmonary toxicity — Potentially fatal pulmonary fibrosis or pneumonitis; baseline and periodic chest X-ray and lung function testing required
- Hepatotoxicity — Elevated liver enzymes common; cirrhosis reported rarely; LFTs must be monitored
- Cardiac pro-arrhythmia — QT prolongation and risk of torsades de pointes; ECG monitoring essential
- Drug–drug interactions — Numerous and clinically significant, including with warfarin (INR potentiation), digoxin (toxicity), and other antiarrhythmics (additive QT effects); a formal DDI review is mandatory before any co-administration
These safety considerations must be formally populated from the SAHPRA-approved PI before this candidate proceeds to any evaluation stage.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN repurposing prediction pipeline could not be executed for amiodarone hydrochloride because the DrugBank identifier is missing — a blocking data gap that prevents knowledge graph traversal and deep learning scoring. With no predicted indications generated, no evidence-based repurposing evaluation can be conducted.
To proceed, the following is needed:
- Populate the DrugBank ID manually — Amiodarone’s DrugBank accession number is DB01118; this should be entered directly into the candidate record to unblock the pipeline.
- Re-run TxGNN prediction modules — Once DB01118 is populated, re-execute both the knowledge graph (KG) and deep learning (DL) prediction workflows to generate repurposing candidates with scored indications.
- Verify SAHPRA registration status — Search the SAHPRA online medicines register directly for “amiodarone” (all salt forms and brand names, e.g., Cordarone, Aratac, Amiodarone Generic); the 0-license result is likely a retrieval error.
- Download and parse the SAHPRA-approved Professional Information (PI) — Required to populate warnings, contraindications, dosage forms, and approved indication text; resolves Data Gap DG001 (currently blocking safety pre-screening).
- Query DrugBank API for structured MOA and pharmacokinetics data — Use DB01118 to retrieve pharmacodynamics, mechanism, absorption/distribution/metabolism/excretion, and toxicity fields; resolves Data Gap DG002.
- Re-submit a complete Evidence Pack — Once steps 1–5 are completed, a full repurposing evaluation report can be generated per standard v4 format.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.